01 · HYP
Particle size & distribution
Measure size using a defined method and conditions; determine whether a reproducible vesicle/particle population exists.
Is there a defined, reproducible dispersed system?
Mechanisms · EPINUTRITION platform
Mechanism maps
Evidence & Hypotheses
A map of ingredient-level mechanisms, published evidence, and open product questions. Literature is distinguished from evidence still needed for the DK-7.4 formulation.
Illustrative TEM: microvilli of a human intestinal cell. Not DK-7.4 experimental data. Louisa Howard & Katherine Connollly · public domain · cropped, toned.
— 01AMPK & mTORC1 · deficit context / product hypothesis
During an energy deficit, the energy sensor AMPK can inhibit mTORC1 through TSC1/TSC2 in context-dependent energy signaling; links to protein synthesis and ubiquitin–proteasome activity depend on model and conditions.
Ingredient literature describes pathways such as PI3K/Akt and mTORC1 in specific models. Any link to DK-7.4 remains a formulation hypothesis until composition, exposure, and a suitable response are measured.
The relationship among these pathways, nutritional exposure, and human outcomes must be measured directly. Ingredient literature is not evidence of efficacy or superiority for the product.
Ingredient literature · LIT
DK-7.4 hypothesis · HYP
Energy deficit · context varies
Energy deficit · context varies
AMPK / energy signaling
PI3K/Akt markers to test
mTORC1 regulation
mTORC1 response to measure
Protein turnover
Human outcome not established
Leucine exposure · literature and formulation question
Dietary protein / free leucine · LITExposure varies
The cited Wolfe and Ely sources do not establish a universal post-absorption fraction or leucine threshold.
DK-7.4 phospholipid matrix · HYPExposure to characterize
Illustrative only; encapsulation, systemic exposure, intracellular delivery, and threshold crossing are not established.
— 02Leucine response & mTORC1 · context-dependent
Response interpretation · no DK-7.4 data
LIT · Interpretation boundary
LIT · Leucine is a nutrient signal; response is context-dependent. No universal 2.5 g threshold, product exposure, or plateau is established here.
Leucine and nutrient sensing
LIT · ingredient / model-dependentHYP · formulation
Leucine is a branched-chain amino acid whose nutrient-sensing relationship with mTORC1via protein Ragulator and complex GATOR2 is described in mechanistic literature. It does not define a universal dose threshold: Wilkinson et al. report no leucine threshold in older adults, and response varies with population, meal, protein, and exercise.
The cited Wolfe 1982 paper does not establish the previously stated 45–55% splanchnic extraction, nor does it compare conventional protein with this matrix. It cannot be used to calculate an “effective” leucine dose.
HYP · Whether the DK-7.4 phospholipid matrix changes digestion, absorption, systemic exposure, or a downstream marker is an open test question. No encapsulation or delivery advantage is inferred.
LIT
Sinalização nutricional
resposta contextual
HYP
Exposição DK-7.4
a caracterizar
DATA
Desfecho do produto
não apresentado
— 03Phospholipid matrix · rationale and test plan
DK-7.4 is described as a phospholipid-powder matrix involving phosphatidylcholine (PC) and phosphatidylserine (PS). The rationale is that phospholipids may organize a matrix; vesicles, encapsulation, stability, and delivery are formulation hypotheses—not established product attributes.
01
Matrix rationale · HYP
LIT · phospholipid property / HYP · this formulationPhospholipids can form bilayers in suitable systems. Whether this powder forms vesicles or protects amino acids under gastric conditions must be measured; no acid-resistance result is claimed.
02
Exposure question · HYP
HYP · DK-7.4 / requires direct measurementLymphatic uptake, systemic appearance, and metabolism are uncharacterized for this formulation. Do not infer lymphatic transport, avoidance of first-pass metabolism, or circulating intact leucine.
03
Cell delivery · not established
HYP · DK-7.4 / requires direct measurementVesicle–cell fusion and intracellular release are not shown for DK-7.4. The cited Wolfe 1982 study does not support a liposomal advantage; cellular delivery would require direct evidence.
Matrix / evidence statusHYP
01 · Declared componentsPC / PS · L-Leucine+ other declared components
02 · Formulation questionDoes a reproducible dispersed system form?
03 · Direct measurementStructure, stability, exposure.
Conceptual matrix · not evidence of vesicles, encapsulation, or delivery.
HYP · formulation test plan
What needs to be measured
These are proposed characterization questions, not reported DK-7.4 results. Acceptance criteria and methods should be defined before testing.
02 · HYP
PDI
Determine polydispersity index and method suitability across independent preparations.
Is distribution sufficiently controlled for the intended use?
03 · HYP
Zeta potential
Characterize surface-charge measurement with medium, dilution, and method recorded.
Does the result support a stability hypothesis under specified conditions?
04 · HYP
Encapsulation / association
Use a validated separation and quantification method for each relevant payload; distinguish encapsulated from free fraction.
Is component association demonstrated and reproducible?
05 · HYP
Physical & chemical stability
Track size, PDI, zeta, leakage/degradation, appearance, and relevant assays over defined storage and stress conditions.
What storage conditions and shelf-life are supportable?
06 · HYP
Microscopy & exposure
Use suitable microscopy to assess morphology; only then design comparative digestion/bioavailability or pharmacokinetic work with prespecified endpoints.
Do not infer absorption or systemic exposure from morphology or encapsulation alone.
— 04Downstream signaling · S6K1 & 4E-BP1
S6K1p70 Ribosomal S6 Kinase 1LIT · model
In studied models, mTORC1-mediated phosphorylation of S6K1 at Thr389 is linked to downstream substrates including rpS6 and eIF4B and regulation of translation. This pathway description does not establish a product response.
→ LIT · Mechanistic pathway; HYP · whether DK-7.4 changes a prespecified marker must be tested.
4E-BP1Eukaryotic Initiation Factor 4E-Binding Protein 1LIT · model
4E-BP1 can bind eIF4E and regulate cap-dependent translation; mTORC1-associated phosphorylation releases this interaction in studied systems. Model-specific mechanism, not a human outcome.
→ LIT · Cell / model mechanism; HYP · formulation and human relevance remain to be established.
Conceptual mechanism · LIT ingredient / HYP formulation
Leucine
exposure to characterize
›
Ragulator / GATOR2
mTOR sensing axis
›
mTORC1
pathway studied
›
S6K1 / 4E-BP1
phosphorylation markers
›
Response to test
no clinical inference
LIT describes ingredient-level pathways; HYP marks the question for DK-7.4. The diagram does not characterize product bioavailability, efficacy, or clinical safety.
Ingredient literature · not product evidence
LIT
Leucine · ingredient literature
Ely et al. (2023) review nutrient regulation in aging, exercise, and unloading contexts. It does not establish a universal 2.5 g threshold or a threefold product effect. Wilkinson et al. (2023) report no leucine threshold in older adults. DOI: 10.1016/j.clnu.2023.08.010; 10.14814/phy2.15775.
Ingredient literature · not product evidence
+0.28kg
Lean mass · isolated HMB meta-analysis
Li et al. (2025): pooled lean-mass estimate from 21 RCTs, n=1,935 participants over 50 years. Appendicular lean mass estimate: +1.56 kg. These estimates concern oral HMB in the included studies only; protocols varied and neither estimate predicts DK-7.4 outcomes. DOI: 10.3389/fnut.2025.1522287.
Ingredient literature · not product evidence
HYP
Phospholipid matrix · formulation question
Welch et al. (2023) reviewed seven randomized trials of phosphatidylserine in sport; evidence was considered insufficient for firm endorsement. The review does not support a ~30% cortisol-reduction claim or an effect of this product. DOI: 10.33545/27077012.2023.v4.i2c.209.
— 05Biochemical Safety Profile
USR
End User
- —Suitability depends on the final label, declared composition, population, and professional guidance.
- —No hormonal, therapeutic, or performance activities are attributed to the formulation without dedicated studies.
- —Safety literature for creatine, BCAAs, and other ingredients must be interpreted by dose, population, and study design.
- —Athletes and technical teams should confirm the requirements of applicable sporting organizations before use.
PRO
Recommending Professional
- —Ingredient mechanistic literature does not replace individual clinical assessment or evidence for the combination.
- —No claims of absence of drug interactions are made for the formulation without specific assessment.
- —Professional discussion should remain limited to declared composition, use context, and ingredient references.
- —Technical documentation must distinguish mechanism, ingredient evidence, formulation characterization, and human outcome.
- —Professionals should follow the standards of their specialty and the product’s official information.
REG
Regulatory Scope
- —O enquadramento e as alegações dependem da composição final, constituintes autorizados, limites, rotulagem e documentação aplicável.
- —For Brazil, product classification and regulatory status require review under RDC 243/2018, IN 28/2018 as amended, RDC 843/2024, IN 281/2024 and other applicable rules.
- —An ingredient’s regulatory status is not authorization to make a claim for the complete formulation.
- —Certifications, quality systems, and traceability must be presented through verifiable documentation.
- —International market assessment requires local review before any communication or distribution.
Regulatory context: RDC 18/2010 was revoked by RDC 243/2018. Brazilian review considers RDC 243/2018, IN 28/2018 as amended, RDC 843/2024, IN 281/2024 and other applicable rules. Product classification, claims and labeling depend on final composition and intended use; this page presents no documentation establishing notification or registration. Ingredient literature is not clinical evidence for the complete formulation.
— 06Professional Context
Access the technical documentation to review ingredient literature, declared composition, and the boundary between published mechanisms and evidence that still needs to be generated for the formulation.
Access Medical Portal →Scientific Literature
Scientific References
Bibliographic DOI records have been checked. Each study's design, population and endpoint constrain the interpretation; a valid DOI does not verify the site's numerical claims or establish a result for DK-7.4.
1
Ely IA, Phillips BE, Smith K, Wilkinson DJ, Piasecki M, Breen L, Larsen MS, Atherton PJ.
A focus on leucine in the nutritional regulation of human skeletal muscle metabolism in ageing, exercise and unloading states.
Clinical Nutrition·2023·42(10):1849–1865
LeucinemTORC1MPSBCAA
2
Li N, Wu X, Zhuang W, et al.
Effects of oral supplementation of β-hydroxy-β-methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis.
Frontiers in Nutrition·2025·12:1522287
HMBLean MassMeta-analysisn=1.935>50 years
3
Welch J, Bashir H, Daniels S.
The effect of phosphatidylserine supplementation on athletic performance: A systematic review of randomized clinical trials.
Journal of Sports Science and Nutrition·2023·4(2):170–175
PhosphatidylserineAthletic Performance7 estudosEvidência insuficiente
4
D'Hulst G, De Bock K.
Resistance exercise enhances long-term mTORC1 sensitivity to leucine.
Molecular Metabolism·2022·66:101615
mTORResistance ExerciseLeucineS6K1
5
Wilkinson K, Koscien CP, Monteyne AJ, Wall BT, Stephens FB.
Association of postprandial postexercise muscle protein synthesis rates with dietary leucine: A systematic review.
Physiological Reports·2023·11(15):e15775
BCAALeucineMPSIsoleucineValine
6
Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW, Tagliabracci VS, Guan KL.
Differential regulation of mTORC1 by leucine and glutamine.
Science·2015·347(6218):194–198
GlutaminemTORC1GATOR2GATOR1
7
Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL.
International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine.
Journal of the International Society of Sports Nutrition·2017·14:18
CreatineISSNPosicionamento científicoSafety em contexto
8
Wolfe RR, Goodenough RD, Wolfe MH, Royle GT, Nadel ER.
Isotopic analysis of leucine and urea metabolism in exercising humans.
Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology·1982·52(2):458–466
LeucineMetabolism durante exercícioAnálise isotópica
References concern published ingredient literature, not studies of the complete formulation. Classification, authorized constituents, claims and notification of any finished supplement require review against current Brazilian rules and product documents.